Status:
TERMINATED
Assay to Measure Beta Blocker Adherence
Lead Sponsor:
Summa Health System
Collaborating Sponsors:
Quest Diagnostics-Nichols Insitute
Conditions:
Congestive Heart Failure
Medication Adherence
Eligibility:
All Genders
18-89 years
Brief Summary
This study will assess the feasibility and efficacy of using serum assay developed by Quest Diagnostics to detect the presence of beta blockers, specifically carvedilol and metoprolol succinate, in pa...
Detailed Description
Patients admitted to the Summa Akron City campus with a primary diagnosis of heart failure will be invited to participate 1 to 2 days prior to expected discharge. A research nurse with the Summa CRC w...
Eligibility Criteria
Inclusion
- Age 18-89
- Admitted for primary diagnosis of heart failure with reduced ejection fraction
- Prescribed carvedilol or metoprolol succinate for beta blocker therapy
- Will be following up at 95 Arch St. Clinic
Exclusion
- Under age 18/over age 89
- Patients that plan to follow up somewhere other than the 95 Arch St. Clinic
- Patients with prior heart transplant or a left ventricular assist device
- Patient is unable to provide consent.
Key Trial Info
Start Date :
March 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 15 2023
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT05251974
Start Date
March 2 2022
End Date
November 15 2023
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Summa Health System
Akron, Ohio, United States, 44304